Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

Relapsed Non Hodgkin Lymphoma Clinical Trial

Official title:

Phase Ⅰ Study of CAR19 T Cells Carrying Cytoplasmic Activated PD-1 in the Treatment of Refractory/Relapsed B Cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03540303
• Other study ID #: HenanCH CAR 2-1
• Status: Recruiting
• Phase: Phase 1
• Start date: April 12, 2018
• Est. completion date: April 30, 2020

Study information

• Verified date: April 2018
• Source: Henan Cancer Hospital
• Contact: Yongping Song, M.D
• Phone: +86-371-65587199
• Email: songyongping2018[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluation of the safety and efficacy of CAR19 T cells carrying cytoplasmic activated PD1 in patients with refractory relapsed B-cell lymphoma

Description:

Although CAR19 T cell therapy brings hope, the patients with refractory/relapsed B-cell lymphoma is still a problem for the current treatment. There are still some patients with poor therapeutic efficacy, and the efficacy of CAR19-T cell therapy remains to be improved. Basic research shows that there is a synergistic effect between CAR-T cell therapy and anti-PD1 pathway, and it did have efficacy in clinic. However, the regimen of CAR19-T cells combined anti-PD1 inhibitors need to be combined with the application of anti-PD1 antibody and culture of CART cells during the treatment, there may be adverse events to PD1 antibodies. In this study, CAR19T cells carrying cytosolic activated PD1 possess the dual effects of CAR19T cells and anti-PD1 or anti-PD-L1 antibodies while overcoming the adverse events of anti-PD1 inhibitors, and might have better efficacy than conventional CAR19T cells plus anti-PD1 or anti-PD-L1 antibody treatment, with fewer side effects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: April 30, 2020
• Est. primary completion date: April 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• 18-70 years old and the expected lifetime >3 months

• Refractory/relapsed CD19 positive B cell lymphoma by pathology

• ECOG score <2

• Measureable lesions according to RECIST 1.1

• Sufficient heart, liver, kidney and bone marrow function (heart: no heart disease or coronary heart disease, patient heart function NYHA grade 1-2; liver: TBIL = 3ULN, AST = 2.5ULN, ALT = 2.5ULN; kidney: Cr= 1.25ULN; bone marrow: WBC = 2.0 × 109/L, Hb = 80 g/L, PLT = 30 × 109/L)

• no serious allergies

• No other serious diseases that conflict with this protocol (eg, autoimmune diseases, immunodeficiency, organ transplantation)

• No other history of malignancy

• No serious mental disorders

• Women of childbearing age must be negative for blood pregnancy test within 7 days and must take appropriated contraceptive measures during and 3 months after the study

• The patient himself agrees to participate in this clinical study and signed the "informed consent"

Exclusion Criteria:

• Lactating women

• Severe infectious or viral diseases (HIV positive, syphilis, etc.)

• Active hepatitis B or C viral hepatitis

• Patients who used high-dose glucocorticoids within 1 week

• Participation in other clinical studies in the past 3 months or having been treated with other gene products

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Non-Hodgkin
• Relapsed Non Hodgkin Lymphoma

Intervention

Drug:
• CAR19 T cells carrying cytoplasmic activated PD-1
step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients. After finishing this, another 6 patients will be enrolled for observation of efficacy.

Locations

Country	Name	City	State
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
Henan Cancer Hospital	The Pregene (ShenZhen) Biotechnology Company, Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	safety: occurrence of study related adverse events	occurrence of study related adverse events	6 months
Secondary	objective response rate	tumor burdens shrink more than 30 percent by RECIST1.1	3 months and 6 months